[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fos23S8SCW1sJ0si8E3vjmodLQNbXynbLCq2Wu8V5oJg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":51,"rows":58},"University of Mississippi Medical Center",[4],125,false,15,10,12709,5,93,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Hypertension",8,{"name":18,"count":19},"Obesity",7,{"name":21,"count":22},"Sickle Cell Disease",4,{"name":24,"count":22},"Asthma",{"name":26,"count":27},"Spinal Cord Injuries",3,{"name":29,"count":27},"Sedentary Behavior",{"name":31,"count":27},"Preeclampsia",{"name":33,"count":34},"PreDiabetes",2,[36,41,46],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06274021","Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury","2025-12-31","Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05687058","Empagliflozin in ESKD - A Feasibility Study","2026-05-04","Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT02989025","Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe\u002FSuperimposed Preeclampsia","2027-01-31","17 OHPC",[52,53,54,55,56,57],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[59,84,109,127,151,169,201,230,265,289,314,343,361,379,405,423,450,474,492,510,537,563,586,610,637,655,677,702,728,746,780,798,816,839,863,881,899,923,951,969,987,1009,1032,1056,1084,1102],{"intervention":50,"totalTrials":60,"cells":61},1,{"EARLY_PHASE1":62,"PHASE1":65,"PHASE2":67,"PHASE3":78,"PHASE4":80,"NA":82},{"trials":63,"activeCount":64},[],0,{"trials":66,"activeCount":64},[],{"trials":68,"activeCount":60,"soonestReadout":49},[69],{"nctId":47,"briefTitle":48,"status":70,"phases":71,"primaryCompletion":49,"completion":49,"start":72,"enrollment":73,"conditions":74,"interventions":77},"RECRUITING",[54],"2017-05-22",60,[75,76],"Pregnancy","Preeclampsia (PE)",[50],{"trials":79,"activeCount":64},[],{"trials":81,"activeCount":64},[],{"trials":83,"activeCount":64},[],{"intervention":45,"totalTrials":60,"cells":85},{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":103,"PHASE4":105,"NA":107},{"trials":87,"activeCount":64},[],{"trials":89,"activeCount":64},[],{"trials":91,"activeCount":60,"soonestReadout":44},[92],{"nctId":42,"briefTitle":43,"status":93,"phases":94,"primaryCompletion":44,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":101},"ACTIVE_NOT_RECRUITING",[53,54],"2026-06-20","2023-11-01",24,[99,100],"Kidney Failure, Chronic","Heart Failure",[45,102],"Empagliflozin 10 mg daily dosing",{"trials":104,"activeCount":64},[],{"trials":106,"activeCount":64},[],{"trials":108,"activeCount":64},[],{"intervention":102,"totalTrials":60,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":121,"PHASE4":123,"NA":125},{"trials":112,"activeCount":64},[],{"trials":114,"activeCount":64},[],{"trials":116,"activeCount":60,"soonestReadout":44},[117],{"nctId":42,"briefTitle":43,"status":93,"phases":118,"primaryCompletion":44,"completion":95,"start":96,"enrollment":97,"conditions":119,"interventions":120},[53,54],[99,100],[45,102],{"trials":122,"activeCount":64},[],{"trials":124,"activeCount":64},[],{"trials":126,"activeCount":64},[],{"intervention":40,"totalTrials":60,"cells":128},{"EARLY_PHASE1":129,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":149},{"trials":130,"activeCount":60,"soonestReadout":39},[131],{"nctId":37,"briefTitle":38,"status":70,"phases":132,"primaryCompletion":39,"completion":39,"start":133,"enrollment":134,"conditions":135,"interventions":139},[52],"2024-03-01",16,[26,136,137,138],"Spinal Cord Injury","Spinal Cord Injury Cervical","Spinal Cord Injury Thoracic",[40,140],"Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine",{"trials":142,"activeCount":64},[],{"trials":144,"activeCount":64},[],{"trials":146,"activeCount":64},[],{"trials":148,"activeCount":64},[],{"trials":150,"activeCount":64},[],{"intervention":140,"totalTrials":60,"cells":152},{"EARLY_PHASE1":153,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":167},{"trials":154,"activeCount":60,"soonestReadout":39},[155],{"nctId":37,"briefTitle":38,"status":70,"phases":156,"primaryCompletion":39,"completion":39,"start":133,"enrollment":134,"conditions":157,"interventions":158},[52],[26,136,137,138],[40,140],{"trials":160,"activeCount":64},[],{"trials":162,"activeCount":64},[],{"trials":164,"activeCount":64},[],{"trials":166,"activeCount":64},[],{"trials":168,"activeCount":64},[],{"intervention":170,"totalTrials":34,"cells":171},"Xolair",{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":199},{"trials":173,"activeCount":64},[],{"trials":175,"activeCount":64},[],{"trials":177,"activeCount":64},[],{"trials":179,"activeCount":64},[],{"trials":181,"activeCount":64},[182,193],{"nctId":183,"briefTitle":184,"status":185,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":192},"NCT00691873","Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids","COMPLETED",[56],"2007-05","2007-10","2006-05",14,[24],[170],{"nctId":194,"briefTitle":195,"status":185,"phases":196,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":197,"interventions":198},"NCT00329381","Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy",[56],[24],[170,170],{"trials":200,"activeCount":64},[],{"intervention":202,"totalTrials":60,"cells":203},"Granulocyte Colony-Stimulating Factor",{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":228},{"trials":205,"activeCount":64},[],{"trials":207,"activeCount":64},[],{"trials":209,"activeCount":64},[],{"trials":211,"activeCount":64},[],{"trials":213,"activeCount":64},[214],{"nctId":215,"briefTitle":216,"status":217,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":227},"NCT03823950","Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients","UNKNOWN",[56],"2021-12","2022-06","2019-02-01",150,[202,224,225,226],"Chemotherapy-induced Neutropenia","Chemotherapy-Induced Febrile Neutropenia","Pediatric Cancer",[202],{"trials":229,"activeCount":64},[],{"intervention":231,"totalTrials":34,"cells":232},"Immulina TM",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":261,"NA":263},{"trials":234,"activeCount":64},[],{"trials":236,"activeCount":64},[],{"trials":238,"activeCount":64},[],{"trials":240,"activeCount":64},[241,251],{"nctId":242,"briefTitle":243,"status":185,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT05524532","Effects of Immulina TM Supplements With PASC Patients",[55],"2025-07-29","2023-07-20",101,[249],"Post Acute COVID-19 Syndrome",[231],{"nctId":252,"briefTitle":253,"status":185,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT05447078","Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection",[55],"2025-12-08","2022-07-01",492,[259],"Healthy Volunteers",[231],{"trials":262,"activeCount":64},[],{"trials":264,"activeCount":64},[],{"intervention":266,"totalTrials":60,"cells":267},"Mulberry Leaf Extract",{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":285,"NA":287},{"trials":269,"activeCount":64},[],{"trials":271,"activeCount":64},[],{"trials":273,"activeCount":64},[],{"trials":275,"activeCount":64},[276],{"nctId":277,"briefTitle":278,"status":185,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":97,"conditions":282,"interventions":284},"NCT00795704","Impact of Mulberry Leaf on Type 2 Diabetes",[54,55],"2010-05","2008-04",[283],"Type 2 Diabetes",[266],{"trials":286,"activeCount":64},[],{"trials":288,"activeCount":64},[],{"intervention":290,"totalTrials":60,"cells":291},"Immulina",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":310,"NA":312},{"trials":293,"activeCount":64},[],{"trials":295,"activeCount":64},[],{"trials":297,"activeCount":64},[],{"trials":299,"activeCount":64},[300],{"nctId":301,"briefTitle":302,"status":185,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT05556967","Identification of Surrogate Blood and\u002For Urine Biomarker for Immulina TM (Trademark) in Normal Humans",[55],"2023-10-19","2023-08-09",20,[308],"Adherence, Patient",[290],{"trials":311,"activeCount":64},[],{"trials":313,"activeCount":64},[],{"intervention":315,"totalTrials":60,"cells":316},"Pterostilbene 50 mg twice daily",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":339,"NA":341},{"trials":318,"activeCount":64},[],{"trials":320,"activeCount":64},[],{"trials":322,"activeCount":64},[],{"trials":324,"activeCount":64},[325],{"nctId":326,"briefTitle":327,"status":185,"phases":328,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":336},"NCT01267227","Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress",[54,55],"2012-02","2010-12",80,[333,334,335],"Hyperlipidemia","Blood Pressure","Oxidative Stress",[315,337,338],"Grape Extract","Pterostilbene 125 mg twice daily",{"trials":340,"activeCount":64},[],{"trials":342,"activeCount":64},[],{"intervention":337,"totalTrials":60,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":357,"NA":359},{"trials":346,"activeCount":64},[],{"trials":348,"activeCount":64},[],{"trials":350,"activeCount":64},[],{"trials":352,"activeCount":64},[353],{"nctId":326,"briefTitle":327,"status":185,"phases":354,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":355,"interventions":356},[54,55],[333,334,335],[315,337,338],{"trials":358,"activeCount":64},[],{"trials":360,"activeCount":64},[],{"intervention":338,"totalTrials":60,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":375,"NA":377},{"trials":364,"activeCount":64},[],{"trials":366,"activeCount":64},[],{"trials":368,"activeCount":64},[],{"trials":370,"activeCount":64},[371],{"nctId":326,"briefTitle":327,"status":185,"phases":372,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":373,"interventions":374},[54,55],[333,334,335],[315,337,338],{"trials":376,"activeCount":64},[],{"trials":378,"activeCount":64},[],{"intervention":380,"totalTrials":60,"cells":381},"Midazolam",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":401,"NA":403},{"trials":383,"activeCount":64},[],{"trials":385,"activeCount":64},[],{"trials":387,"activeCount":64},[],{"trials":389,"activeCount":64},[390],{"nctId":391,"briefTitle":392,"status":185,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},"NCT02250703","Intranasal Dexmedetomidine Premedication in Children",[55],"2016-09","2014-09",75,[398],"Preoperative Sedation",[380,400],"Dexmedetomidine",{"trials":402,"activeCount":64},[],{"trials":404,"activeCount":64},[],{"intervention":400,"totalTrials":60,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":419,"NA":421},{"trials":408,"activeCount":64},[],{"trials":410,"activeCount":64},[],{"trials":412,"activeCount":64},[],{"trials":414,"activeCount":64},[415],{"nctId":391,"briefTitle":392,"status":185,"phases":416,"primaryCompletion":394,"completion":394,"start":395,"enrollment":396,"conditions":417,"interventions":418},[55],[398],[380,400],{"trials":420,"activeCount":64},[],{"trials":422,"activeCount":64},[],{"intervention":424,"totalTrials":60,"cells":425},"Ropivacaine",{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":446,"NA":448},{"trials":427,"activeCount":64},[],{"trials":429,"activeCount":64},[],{"trials":431,"activeCount":64},[],{"trials":433,"activeCount":64},[434],{"nctId":435,"briefTitle":436,"status":437,"phases":438,"primaryCompletion":439,"completion":440,"start":441,"enrollment":64,"conditions":442,"interventions":445},"NCT02506855","Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP)","WITHDRAWN",[55],"2016-01","2016-06","2015-06",[443,444],"Postoperative Pain","Postoperative Nausea and Vomiting",[424],{"trials":447,"activeCount":64},[],{"trials":449,"activeCount":64},[],{"intervention":451,"totalTrials":60,"cells":452},"propofol",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":470,"NA":472},{"trials":454,"activeCount":64},[],{"trials":456,"activeCount":64},[],{"trials":458,"activeCount":64},[],{"trials":460,"activeCount":64},[461],{"nctId":462,"briefTitle":463,"status":437,"phases":464,"primaryCompletion":465,"completion":465,"start":465,"enrollment":64,"conditions":466,"interventions":467},"NCT01248234","Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone?",[55],"2012-07",[15],[451,468,469],"Etomidate","Propofol and Etomidate",{"trials":471,"activeCount":64},[],{"trials":473,"activeCount":64},[],{"intervention":468,"totalTrials":60,"cells":475},{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":488,"NA":490},{"trials":477,"activeCount":64},[],{"trials":479,"activeCount":64},[],{"trials":481,"activeCount":64},[],{"trials":483,"activeCount":64},[484],{"nctId":462,"briefTitle":463,"status":437,"phases":485,"primaryCompletion":465,"completion":465,"start":465,"enrollment":64,"conditions":486,"interventions":487},[55],[15],[451,468,469],{"trials":489,"activeCount":64},[],{"trials":491,"activeCount":64},[],{"intervention":469,"totalTrials":60,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":506,"NA":508},{"trials":495,"activeCount":64},[],{"trials":497,"activeCount":64},[],{"trials":499,"activeCount":64},[],{"trials":501,"activeCount":64},[502],{"nctId":462,"briefTitle":463,"status":437,"phases":503,"primaryCompletion":465,"completion":465,"start":465,"enrollment":64,"conditions":504,"interventions":505},[55],[15],[451,468,469],{"trials":507,"activeCount":64},[],{"trials":509,"activeCount":64},[],{"intervention":511,"totalTrials":60,"cells":512},"GLP-1 receptor agonist",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":514,"activeCount":64},[],{"trials":516,"activeCount":64},[],{"trials":518,"activeCount":64},[519],{"nctId":520,"briefTitle":521,"status":522,"phases":523,"primaryCompletion":524,"completion":525,"start":526,"enrollment":11,"conditions":527,"interventions":530},"NCT04964388","Effect of GLP-1 Receptor Agonists on Trabecular Bone Score","TERMINATED",[54],"2023-05-01","2023-07-01","2021-11-09",[528,529],"Osteoporosis, Postmenopausal","Diabetes Mellitus, Type 2",[511],{"trials":532,"activeCount":64},[],{"trials":534,"activeCount":64},[],{"trials":536,"activeCount":64},[],{"intervention":538,"totalTrials":60,"cells":539},"Levo-Carnitine",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":557,"PHASE4":559,"NA":561},{"trials":541,"activeCount":64},[],{"trials":543,"activeCount":64},[],{"trials":545,"activeCount":64},[546],{"nctId":547,"briefTitle":548,"status":185,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":556},"NCT01665092","Rapid Administration of Carnitine in sEpsis",[54],"2018-03","2019-03","2013-01",250,[555],"Septic Shock",[538],{"trials":558,"activeCount":64},[],{"trials":560,"activeCount":64},[],{"trials":562,"activeCount":64},[],{"intervention":564,"totalTrials":60,"cells":565},"Intravenous citrulline",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":584},{"trials":567,"activeCount":64},[],{"trials":569,"activeCount":64},[570],{"nctId":571,"briefTitle":572,"status":185,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":22,"conditions":576,"interventions":577},"NCT02697240","A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome",[53],"2017-04","2016-02",[21],[564],{"trials":579,"activeCount":64},[],{"trials":581,"activeCount":64},[],{"trials":583,"activeCount":64},[],{"trials":585,"activeCount":64},[],{"intervention":587,"totalTrials":60,"cells":588},"Azithromycin",{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":608},{"trials":590,"activeCount":64},[],{"trials":592,"activeCount":64},[593],{"nctId":594,"briefTitle":595,"status":437,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":64,"conditions":599,"interventions":601},"NCT02630394","A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease",[53],"2017-12-31","2015-09",[21,600],"Acute Chest Syndrome",[587],{"trials":603,"activeCount":64},[],{"trials":605,"activeCount":64},[],{"trials":607,"activeCount":64},[],{"trials":609,"activeCount":64},[],{"intervention":611,"totalTrials":60,"cells":612},"Low dose sildenafil citrate",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":629,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":614,"activeCount":64},[],{"trials":616,"activeCount":64},[617],{"nctId":618,"briefTitle":619,"status":217,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":97,"conditions":624,"interventions":627},"NCT03028298","Sildenafil for DCI",[53],"2022-12","2023-07","2016-12",[625,626],"Subarachnoid Hemorrhage","Cerebral Vasospasm",[611,628],"High dose sildenafil citrate",{"trials":630,"activeCount":64},[],{"trials":632,"activeCount":64},[],{"trials":634,"activeCount":64},[],{"trials":636,"activeCount":64},[],{"intervention":628,"totalTrials":60,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":653},{"trials":640,"activeCount":64},[],{"trials":642,"activeCount":64},[643],{"nctId":618,"briefTitle":619,"status":217,"phases":644,"primaryCompletion":621,"completion":622,"start":623,"enrollment":97,"conditions":645,"interventions":646},[53],[625,626],[611,628],{"trials":648,"activeCount":64},[],{"trials":650,"activeCount":64},[],{"trials":652,"activeCount":64},[],{"trials":654,"activeCount":64},[],{"intervention":656,"totalTrials":60,"cells":657},"Oral L-citrulline",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":669,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":659,"activeCount":64},[],{"trials":661,"activeCount":64},[662],{"nctId":663,"briefTitle":664,"status":437,"phases":665,"primaryCompletion":597,"completion":597,"start":666,"enrollment":64,"conditions":667,"interventions":668},"NCT02659644","A Study of Oral L-citrulline in Sickle Cell Disease",[53],"2015-12",[21],[656],{"trials":670,"activeCount":64},[],{"trials":672,"activeCount":64},[],{"trials":674,"activeCount":64},[],{"trials":676,"activeCount":64},[],{"intervention":678,"totalTrials":60,"cells":679},"vancomycin-tobramycin-itraconazole",{"EARLY_PHASE1":680,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":681,"activeCount":64},[682],{"nctId":683,"briefTitle":684,"status":217,"phases":685,"primaryCompletion":686,"completion":621,"start":687,"enrollment":688,"conditions":689,"interventions":691},"NCT05076955","Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy",[52],"2022-08","2021-03-31",100,[690],"Diabetic Foot Ulcer",[678],{"trials":693,"activeCount":64},[],{"trials":695,"activeCount":64},[],{"trials":697,"activeCount":64},[],{"trials":699,"activeCount":64},[],{"trials":701,"activeCount":64},[],{"intervention":703,"totalTrials":60,"cells":704},"Sildenafil 100 mg",{"EARLY_PHASE1":705,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":706,"activeCount":64},[707],{"nctId":708,"briefTitle":709,"status":522,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":16,"conditions":713,"interventions":716},"NCT04770155","Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1",[52],"2021-09-20","2021-05-27",[714,715],"Vascular Function","Racial Disparity",[703,717],"Bosentan 125 mg",{"trials":719,"activeCount":64},[],{"trials":721,"activeCount":64},[],{"trials":723,"activeCount":64},[],{"trials":725,"activeCount":64},[],{"trials":727,"activeCount":64},[],{"intervention":717,"totalTrials":60,"cells":729},{"EARLY_PHASE1":730,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":731,"activeCount":64},[732],{"nctId":708,"briefTitle":709,"status":522,"phases":733,"primaryCompletion":711,"completion":711,"start":712,"enrollment":16,"conditions":734,"interventions":735},[52],[714,715],[703,717],{"trials":737,"activeCount":64},[],{"trials":739,"activeCount":64},[],{"trials":741,"activeCount":64},[],{"trials":743,"activeCount":64},[],{"trials":745,"activeCount":64},[],{"intervention":747,"totalTrials":34,"cells":748},"Nebivolol",{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":750,"activeCount":64},[],{"trials":752,"activeCount":64},[],{"trials":754,"activeCount":64},[],{"trials":756,"activeCount":64},[],{"trials":758,"activeCount":64},[],{"trials":760,"activeCount":64},[761,770],{"nctId":762,"briefTitle":763,"status":522,"phases":764,"primaryCompletion":765,"completion":765,"start":766,"enrollment":60,"conditions":767,"interventions":768},"NCT00849810","Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate",[57],"2010-11","2009-01",[15],[769,747],"Metoprolol",{"nctId":771,"briefTitle":772,"status":437,"phases":773,"primaryCompletion":774,"completion":775,"start":776,"enrollment":64,"conditions":777,"interventions":778},"NCT01076140","Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab",[57],"2011-01","2011-08","2010-02",[15],[747,779],"Lisinopril",{"intervention":769,"totalTrials":60,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":783,"activeCount":64},[],{"trials":785,"activeCount":64},[],{"trials":787,"activeCount":64},[],{"trials":789,"activeCount":64},[],{"trials":791,"activeCount":64},[],{"trials":793,"activeCount":64},[794],{"nctId":762,"briefTitle":763,"status":522,"phases":795,"primaryCompletion":765,"completion":765,"start":766,"enrollment":60,"conditions":796,"interventions":797},[57],[15],[769,747],{"intervention":779,"totalTrials":60,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":801,"activeCount":64},[],{"trials":803,"activeCount":64},[],{"trials":805,"activeCount":64},[],{"trials":807,"activeCount":64},[],{"trials":809,"activeCount":64},[],{"trials":811,"activeCount":64},[812],{"nctId":771,"briefTitle":772,"status":437,"phases":813,"primaryCompletion":774,"completion":775,"start":776,"enrollment":64,"conditions":814,"interventions":815},[57],[15],[747,779],{"intervention":817,"totalTrials":60,"cells":818},"Dexamethasone",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":820,"activeCount":64},[],{"trials":822,"activeCount":64},[],{"trials":824,"activeCount":64},[],{"trials":826,"activeCount":64},[],{"trials":828,"activeCount":64},[],{"trials":830,"activeCount":64},[831],{"nctId":832,"briefTitle":833,"status":522,"phases":834,"primaryCompletion":835,"completion":835,"start":329,"enrollment":60,"conditions":836,"interventions":838},"NCT02027272","Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):",[57],"2013-12",[837],"Eclampsia",[817],{"intervention":840,"totalTrials":60,"cells":841},"eplerenone, amlodipine",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":843,"activeCount":64},[],{"trials":845,"activeCount":64},[],{"trials":847,"activeCount":64},[],{"trials":849,"activeCount":64},[],{"trials":851,"activeCount":64},[],{"trials":853,"activeCount":64},[854],{"nctId":855,"briefTitle":856,"status":522,"phases":857,"primaryCompletion":858,"completion":858,"start":766,"enrollment":9,"conditions":859,"interventions":860},"NCT00825188","A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives",[57],"2014-03",[18,15],[840,861,861,862],"eplerenone","amlodipine",{"intervention":861,"totalTrials":60,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":866,"activeCount":64},[],{"trials":868,"activeCount":64},[],{"trials":870,"activeCount":64},[],{"trials":872,"activeCount":64},[],{"trials":874,"activeCount":64},[],{"trials":876,"activeCount":64},[877],{"nctId":855,"briefTitle":856,"status":522,"phases":878,"primaryCompletion":858,"completion":858,"start":766,"enrollment":9,"conditions":879,"interventions":880},[57],[18,15],[840,861,861,862],{"intervention":862,"totalTrials":60,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":893},{"trials":884,"activeCount":64},[],{"trials":886,"activeCount":64},[],{"trials":888,"activeCount":64},[],{"trials":890,"activeCount":64},[],{"trials":892,"activeCount":64},[],{"trials":894,"activeCount":64},[895],{"nctId":855,"briefTitle":856,"status":522,"phases":896,"primaryCompletion":858,"completion":858,"start":766,"enrollment":9,"conditions":897,"interventions":898},[57],[18,15],[840,861,861,862],{"intervention":900,"totalTrials":60,"cells":901},"febuxostat",{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":903,"activeCount":64},[],{"trials":905,"activeCount":64},[],{"trials":907,"activeCount":64},[],{"trials":909,"activeCount":64},[],{"trials":911,"activeCount":64},[],{"trials":913,"activeCount":64},[914],{"nctId":915,"briefTitle":916,"status":522,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":60,"conditions":920,"interventions":922},"NCT01701622","The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study",[57],"2011-10","2010-01",[334,921],"Gout",[900],{"intervention":924,"totalTrials":60,"cells":925},"1 Magnesium Sulfate",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":927,"activeCount":64},[],{"trials":929,"activeCount":64},[],{"trials":931,"activeCount":64},[],{"trials":933,"activeCount":64},[],{"trials":935,"activeCount":64},[],{"trials":937,"activeCount":64},[938],{"nctId":939,"briefTitle":940,"status":185,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":948},"NCT00811057","Tocolysis for Preterm Labor",[57],"2009-06","2010-06","2004-06",301,[947],"Preterm Labor",[924,949,950],"Nifedipine","Indomethacin",{"intervention":949,"totalTrials":60,"cells":952},{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":954,"activeCount":64},[],{"trials":956,"activeCount":64},[],{"trials":958,"activeCount":64},[],{"trials":960,"activeCount":64},[],{"trials":962,"activeCount":64},[],{"trials":964,"activeCount":64},[965],{"nctId":939,"briefTitle":940,"status":185,"phases":966,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":967,"interventions":968},[57],[947],[924,949,950],{"intervention":950,"totalTrials":60,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":972,"activeCount":64},[],{"trials":974,"activeCount":64},[],{"trials":976,"activeCount":64},[],{"trials":978,"activeCount":64},[],{"trials":980,"activeCount":64},[],{"trials":982,"activeCount":64},[983],{"nctId":939,"briefTitle":940,"status":185,"phases":984,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":985,"interventions":986},[57],[947],[924,949,950],{"intervention":988,"totalTrials":60,"cells":989},"Omalizumab",{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":991,"activeCount":64},[],{"trials":993,"activeCount":64},[],{"trials":995,"activeCount":64},[],{"trials":997,"activeCount":64},[],{"trials":999,"activeCount":64},[],{"trials":1001,"activeCount":64},[1002],{"nctId":1003,"briefTitle":1004,"status":522,"phases":1005,"primaryCompletion":188,"completion":188,"start":1006,"enrollment":331,"conditions":1007,"interventions":1008},"NCT00226200","Soluble CD23 Expression in Asthma Patients Treated With OMA",[57],"2004-11",[24],[988],{"intervention":1010,"totalTrials":60,"cells":1011},"Progesterone",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1022},{"trials":1013,"activeCount":64},[],{"trials":1015,"activeCount":64},[],{"trials":1017,"activeCount":64},[],{"trials":1019,"activeCount":64},[],{"trials":1021,"activeCount":64},[],{"trials":1023,"activeCount":64},[1024],{"nctId":1025,"briefTitle":1026,"status":185,"phases":1027,"primaryCompletion":919,"completion":943,"start":944,"enrollment":1028,"conditions":1029,"interventions":1031},"NCT00830765","The Use of Progesterone to Reduce Preterm Birth",[57],144,[1030],"Preterm Birth",[1010],{"intervention":1033,"totalTrials":60,"cells":1034},"Orotic acid and Glutathione-",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1036,"activeCount":64},[],{"trials":1038,"activeCount":64},[],{"trials":1040,"activeCount":64},[],{"trials":1042,"activeCount":64},[],{"trials":1044,"activeCount":64},[],{"trials":1046,"activeCount":64},[1047],{"nctId":1048,"briefTitle":1049,"status":185,"phases":1050,"completion":1051,"start":1052,"enrollment":688,"conditions":1053,"interventions":1055},"NCT00227058","Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis",[57],"2005-11","2005-01",[1054],"Seasonal Allergic Rhinitis",[1033],{"intervention":1057,"totalTrials":60,"cells":1058},"Local Anesthetic Ropivacaine",{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1065,"PHASE4":1067,"NA":1069},{"trials":1060,"activeCount":64},[],{"trials":1062,"activeCount":64},[],{"trials":1064,"activeCount":64},[],{"trials":1066,"activeCount":64},[],{"trials":1068,"activeCount":64},[],{"trials":1070,"activeCount":64},[1071],{"nctId":1072,"briefTitle":1073,"status":522,"phases":1074,"primaryCompletion":441,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1081},"NCT02236130","Peripheral Nerve Blocks in Pediatric Orthopedic Patients",[57],"2015-10","2014-06",49,[1079,1080],"Pediatric Extremity Fracture","Pediatric Extremity Soft Tissue Injury",[1057,1082,1083],"Opioids Morphine","Oral pain medication Acetaminophen with Hydrocodone",{"intervention":1082,"totalTrials":60,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1087,"activeCount":64},[],{"trials":1089,"activeCount":64},[],{"trials":1091,"activeCount":64},[],{"trials":1093,"activeCount":64},[],{"trials":1095,"activeCount":64},[],{"trials":1097,"activeCount":64},[1098],{"nctId":1072,"briefTitle":1073,"status":522,"phases":1099,"primaryCompletion":441,"completion":1075,"start":1076,"enrollment":1077,"conditions":1100,"interventions":1101},[57],[1079,1080],[1057,1082,1083],{"intervention":1083,"totalTrials":60,"cells":1103},{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1105,"activeCount":64},[],{"trials":1107,"activeCount":64},[],{"trials":1109,"activeCount":64},[],{"trials":1111,"activeCount":64},[],{"trials":1113,"activeCount":64},[],{"trials":1115,"activeCount":64},[1116],{"nctId":1072,"briefTitle":1073,"status":522,"phases":1117,"primaryCompletion":441,"completion":1075,"start":1076,"enrollment":1077,"conditions":1118,"interventions":1119},[57],[1079,1080],[1057,1082,1083]]